Welcome to LookChem.com Sign In|Join Free
  • or
1-benzyl-4-methyl-1,4-azaphosphinane 4-oxide is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

945459-79-0

Post Buying Request

945459-79-0 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

945459-79-0 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 945459-79-0 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 9,4,5,4,5 and 9 respectively; the second part has 2 digits, 7 and 9 respectively.
Calculate Digit Verification of CAS Registry Number 945459-79:
(8*9)+(7*4)+(6*5)+(5*4)+(4*5)+(3*9)+(2*7)+(1*9)=220
220 % 10 = 0
So 945459-79-0 is a valid CAS Registry Number.

945459-79-0Relevant academic research and scientific papers

PHOSPHOROUS DERIVATIVES AS KINASE INHIBITORS

-

Paragraph 0535; 0673, (2015/09/22)

The invention features compounds of the general formula: in which the variable groups are as defined herein, and to their preparation and use.

PHOSPHORUS CONTAINING QUINAZOLINE COMPOUNDS AND METHODS OF USE

-

Page/Page column 42, (2011/02/24)

Disclosed are novel quinazoline derivatives containing phosphorus substitutions and methods for the treatment of hyperproliferative diseases (e.g. cancer) using the compounds. These compounds are type I receptor protein kinase inhibitors useful in treating disorders related to abnormal protein kinase activities such as cancer and inflammation in mammals. Also disclosed are pharmaceutical compositions containing the compounds, methods for the preparation of the compounds and their pharmaceutically acceptable salts.

INHIBITORS OF TYROSINE KINASES AND USES THEREOF

-

Page/Page column 97, (2008/06/13)

Disclosed herein are compounds that inhibit the activity of particular tyrosine kinases. Methods for the preparation of such compounds are disclosed. Also disclosed are pharmaceutical compositions that include the compounds. Methods of using the compounds disclosed, alone or in combination with other therapeutic agents, for the treatment of tyrosine kinase-rnediated diseases or conditions or tyrosine, kinase-dependent diseases or conditions are provided.

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 945459-79-0